These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 30467061)

  • 41. Pneumococcal Vaccines.
    Briles DE; Paton JC; Mukerji R; Swiatlo E; Crain MJ
    Microbiol Spectr; 2019 Nov; 7(6):. PubMed ID: 31858954
    [No Abstract]   [Full Text] [Related]  

  • 42. Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: A randomized, open-label, non-inferiority trial.
    Nakashima K; Aoshima M; Ohfuji S; Yamawaki S; Nemoto M; Hasegawa S; Noma S; Misawa M; Hosokawa N; Yaegashi M; Otsuka Y
    Hum Vaccin Immunother; 2018; 14(8):1923-1930. PubMed ID: 29561248
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A bivalent conjugate vaccine containing PspA families 1 and 2 has the potential to protect against a wide range of Streptococcus pneumoniae strains and Salmonella Typhi.
    Kothari N; Kothari S; Choi YJ; Dey A; Briles DE; Rhee DK; Carbis R
    Vaccine; 2015 Feb; 33(6):783-8. PubMed ID: 25545593
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety, reactogenicity and immunogenicity of two investigational pneumococcal protein-based vaccines: Results from a randomized phase II study in infants.
    Prymula R; Szenborn L; Silfverdal SA; Wysocki J; Albrecht P; Traskine M; Gardev A; Song Y; Borys D
    Vaccine; 2017 Aug; 35(35 Pt B):4603-4611. PubMed ID: 28729019
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Protection Elicited by Nasal Immunization with Recombinant Pneumococcal Surface Protein A (rPspA) Adjuvanted with Whole-Cell Pertussis Vaccine (wP) against Co-Colonization of Mice with Streptococcus pneumoniae.
    Tostes RO; Rodrigues TC; da Silva JB; Schanoski AS; Oliveira ML; Miyaji EN
    PLoS One; 2017; 12(1):e0170157. PubMed ID: 28103277
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serum samples from infants vaccinated with a pneumococcal conjugate vaccine, PncT, protect mice against invasive infection caused by Streptococcus pneumoniae serotypes 6A and 6B.
    Saeland E; Jakobsen H; Ingolfsdottir G; Sigurdardottir ST; Jonsdottir I
    J Infect Dis; 2001 Jan; 183(2):253-260. PubMed ID: 11110649
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
    Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of Immunogenicity and Protection of Two Pneumococcal Protein Vaccines Based on PsaA and PspA.
    Yu J; Li B; Chen X; Lu J; Wang D; Gu T; Kong W; Wu Y
    Infect Immun; 2018 Jun; 86(6):. PubMed ID: 29610257
    [No Abstract]   [Full Text] [Related]  

  • 49. Synthesis and delivery of
    Su H; Liu Q; Bian X; Wang S; Curtiss R; Kong Q
    Proc Natl Acad Sci U S A; 2021 Jan; 118(2):. PubMed ID: 33380455
    [No Abstract]   [Full Text] [Related]  

  • 50. Characterization of the antibody response elicited by immunization with pneumococcal surface protein A (PspA) as recombinant protein or DNA vaccine and analysis of protection against an intranasal lethal challenge with Streptococcus pneumoniae.
    Vadesilho CF; Ferreira DM; Moreno AT; Chavez-Olortegui C; Machado de Avila RA; Oliveira ML; Ho PL; Miyaji EN
    Microb Pathog; 2012; 53(5-6):243-9. PubMed ID: 22981893
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Streptococcus pneumoniae serotype distribution in Vojvodina before the introduction of pneumococcal conjugate vaccines into the National Immunization Program.
    Petrović V; Šeguljev Z; Ristić M; Djekić-Malbaša J; Radosavljević B; Medić D; Mihajlović-Ukropina M; Hadnadjev M; Gajic I; Opavski N
    Srp Arh Celok Lek; 2016; 144(9-10):521-6. PubMed ID: 29653038
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Membrane particles evoke a serotype-independent cross-protection against pneumococcal infection that is dependent on the conserved lipoproteins MalX and PrsA.
    Narciso AR; Iovino F; Thorsdottir S; Mellroth P; Codemo M; Spoerry C; Righetti F; Muschiol S; Normark S; Nannapaneni P; Henriques-Normark B
    Proc Natl Acad Sci U S A; 2022 Jun; 119(23):e2122386119. PubMed ID: 35648835
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immune response to pneumococcal conjugate vaccination in asplenic individuals.
    Stanford E; Print F; Falconer M; Lamden K; Ghebrehewet S; Phin N; Baxter D; Helbert M; McCann R; Andrews N; Balmer P; Borrow R; Kaczmarski E
    Hum Vaccin; 2009 Feb; 5(2):85-91. PubMed ID: 18758242
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vaccination of adults with 23-valent pneumococcal polysaccharide vaccine induces robust antibody responses against pneumococcal serotypes associated with serious clinical outcomes.
    Ciprero KL; Marchese RD; Richard P; Baudin M; Sterling TM; Manoff SB; Radley D; Stek JE; Soubeyrand B; Grabenstein JD; Samson SI; Musey LK
    Hum Vaccin Immunother; 2016 Aug; 12(8):2135-2141. PubMed ID: 27002793
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
    Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T
    Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Protective Immune Responses Elicited by Fusion Protein Containing PsaA and PspA Fragments.
    Lu J; Sun T; Wang D; Dong Y; Xu M; Hou H; Kong FT; Liang C; Gu T; Chen P; Sun S; Lv X; Jiang C; Kong W; Wu Y
    Immunol Invest; 2015; 44(5):482-96. PubMed ID: 26107747
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Understanding host immune responses to pneumococcal proteins in the upper respiratory tract to develop serotype-independent pneumococcal vaccines.
    Lagousi T; Basdeki P; De Jonge MI; Spoulou V
    Expert Rev Vaccines; 2020 Oct; 19(10):959-972. PubMed ID: 33107359
    [No Abstract]   [Full Text] [Related]  

  • 58. IL-17A and complement contribute to killing of pneumococci following immunization with a pneumococcal whole cell vaccine.
    Campos IB; Herd M; Moffitt KL; Lu YJ; Darrieux M; Malley R; Leite LC; Gonçalves VM
    Vaccine; 2017 Mar; 35(9):1306-1315. PubMed ID: 28161422
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of previous vaccination with pneumococcal conjugate vaccine on pneumococcal polysaccharide vaccine antibody responses.
    Schaballie H; Wuyts G; Dillaerts D; Frans G; Moens L; Proesmans M; Vermeulen F; De Boeck K; Meyts I; Bossuyt X
    Clin Exp Immunol; 2016 Aug; 185(2):180-9. PubMed ID: 26939935
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination.
    Wysocki J; Brzostek J; Szymański H; Tetiurka B; Toporowska-Kowalska E; Wasowska-Królikowska K; Sarkozy DA; Giardina PC; Gruber WC; Emini EA; Scott DA
    Vaccine; 2015 Mar; 33(14):1719-25. PubMed ID: 25698485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.